Skip to main content
Top
Published in: Current Geriatrics Reports 3/2019

01-09-2019 | Central Nervous System Trauma | Surgical Care (F Luchette and R Gonzalez, Section Editors)

Consideration of Anticoagulation: Surgical Care for the Elderly in Current Geriatrics Reports

Authors: Jared R. Gallaher, Joanna Grudziak, Martin A. Schreiber

Published in: Current Geriatrics Reports | Issue 3/2019

Login to get access

Abstract

Introduction

The geriatric population in the USA is growing at a dramatic rate. As this segment of the population increases in number, surgical providers will increasingly treat and evaluate patients with age-specific needs that affect surgical or trauma management. Consequently, surgeons should be familiar with trends in prescribing oral anticoagulants (OACs), their association with outcomes, and the guidelines for reversing and prescribing these medications.

Results

Warfarin was the only oral anticoagulant available in the USA until 2010 when non-vitamin K antagonist oral anticoagulants (NOACs) were introduced to the market. Since then, they have rapidly gained a majority of the US market share. The implications of NOAC use on bleeding complications such as in traumatic brain injury (TBI) are unclear, but evidence suggests that NOACs may be safer than warfarin. Guidelines for anticoagulation reversal in life-threatening bleeding associated with warfarin are well established, but optimal utilization is evolving for most NOAC agents.

Conclusion

The use of anticoagulation therapy has changed dramatically over the last decade. These changes are multifactorial and include the increasing prevalence of OAC use, and the introduction of NOACs. Consequently, challenges associated with managing OAC in the elderly will only become more complicated over time. Surgical providers need to be aware of these changes and update their practice on the shifting epidemiology of this population, evolving guidelines, and new reversal agents.
Literature
2.
go back to reference Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circulation: Cardiovascular Quality and Outcomes. 2012;5(5):615–21. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circulation: Cardiovascular Quality and Outcomes. 2012;5(5):615–21.
3.
go back to reference Berndtson AE, Coimbra R. The epidemic of pre-injury oral antiplatelet and anticoagulant use. Eur J Trauma Emerg Surg. 2014;40(6):657–69.CrossRefPubMed Berndtson AE, Coimbra R. The epidemic of pre-injury oral antiplatelet and anticoagulant use. Eur J Trauma Emerg Surg. 2014;40(6):657–69.CrossRefPubMed
4.
go back to reference •• Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010–2017. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2018;38(9):907–20 The authors’ analysis of US medical and pharmacy claims between 2010 and 2017 demonstrated a dramatic increase in NOAC prescriptions since their introduction in 2010. Warfarin use decreased from a nearly 100% OAC market share in 2010 to only 21% in 2017. This decrease was accompanied by a concomitant increase in NOAC prescriptions, especially apixaban. CrossRef •• Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010–2017. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2018;38(9):907–20 The authors’ analysis of US medical and pharmacy claims between 2010 and 2017 demonstrated a dramatic increase in NOAC prescriptions since their introduction in 2010. Warfarin use decreased from a nearly 100% OAC market share in 2010 to only 21% in 2017. This decrease was accompanied by a concomitant increase in NOAC prescriptions, especially apixaban. CrossRef
6.
go back to reference Kuhne CA, Ruchholtz S, Kaiser GM, Nast-Kolb D. Mortality in severely injured elderly trauma patients—when does age become a risk factor? World J Surg. 2005;29(11):1476–82.CrossRefPubMed Kuhne CA, Ruchholtz S, Kaiser GM, Nast-Kolb D. Mortality in severely injured elderly trauma patients—when does age become a risk factor? World J Surg. 2005;29(11):1476–82.CrossRefPubMed
7.
go back to reference Ferrera PC, Bartfield JM, D'andrea CC. Outcomes of admitted geriatric trauma victims. Am J Emerg Med. 2000;18(5):575–80.CrossRefPubMed Ferrera PC, Bartfield JM, D'andrea CC. Outcomes of admitted geriatric trauma victims. Am J Emerg Med. 2000;18(5):575–80.CrossRefPubMed
11.
go back to reference Gardner RC, Dams-O'Connor K, Morrissey MR, Manley GT. Geriatric traumatic brain injury: epidemiology, outcomes, knowledge gaps, and future directions. J Neurotrauma. 2018;35(7):889–906.CrossRefPubMedCentralPubMed Gardner RC, Dams-O'Connor K, Morrissey MR, Manley GT. Geriatric traumatic brain injury: epidemiology, outcomes, knowledge gaps, and future directions. J Neurotrauma. 2018;35(7):889–906.CrossRefPubMedCentralPubMed
13.
go back to reference Dossett LA, Riesel JN, Griffin MR, Cotton BA. Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank. Arch Surg (Chicago, Ill : 1960). 2011;146(5):565–70.CrossRef Dossett LA, Riesel JN, Griffin MR, Cotton BA. Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank. Arch Surg (Chicago, Ill : 1960). 2011;146(5):565–70.CrossRef
14.
go back to reference Inui TS, Parina R, Chang DC, Inui TS, Coimbra R. Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter. J Trauma Acute Care Surg. 2014;76(3):642–50.CrossRefPubMed Inui TS, Parina R, Chang DC, Inui TS, Coimbra R. Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter. J Trauma Acute Care Surg. 2014;76(3):642–50.CrossRefPubMed
15.
go back to reference Chenoweth JA, Gaona SD, Faul M, Holmes JF, Nishijima DK. Incidence of delayed intracranial hemorrhage in older patients after blunt head trauma. JAMA Surg. 2018;153(6):570–5.CrossRefPubMedPubMedCentral Chenoweth JA, Gaona SD, Faul M, Holmes JF, Nishijima DK. Incidence of delayed intracranial hemorrhage in older patients after blunt head trauma. JAMA Surg. 2018;153(6):570–5.CrossRefPubMedPubMedCentral
16.
go back to reference Tollefsen MH, Vik A, Skandsen T, Sandrød O, Deane SF, Rao V, et al. Patients with moderate and severe traumatic brain injury: impact of preinjury platelet inhibitor or warfarin treatment. World neurosurgery. 2018;114:e209–17.CrossRefPubMed Tollefsen MH, Vik A, Skandsen T, Sandrød O, Deane SF, Rao V, et al. Patients with moderate and severe traumatic brain injury: impact of preinjury platelet inhibitor or warfarin treatment. World neurosurgery. 2018;114:e209–17.CrossRefPubMed
17.
go back to reference Boltz MM, Podany AB, Hollenbeak CS, Armen SB. Injuries and outcomes associated with traumatic falls in the elderly population on oral anticoagulant therapy. Injury. 2015;46(9):1765–71.CrossRefPubMed Boltz MM, Podany AB, Hollenbeak CS, Armen SB. Injuries and outcomes associated with traumatic falls in the elderly population on oral anticoagulant therapy. Injury. 2015;46(9):1765–71.CrossRefPubMed
18.
go back to reference Howard JL, Cipolle MD, Horvat SA, et al. Preinjury warfarin worsens outcome in elderly patients who fall from standing. J Trauma. 2009;66(6):1518–22 discussion1523–4.CrossRefPubMed Howard JL, Cipolle MD, Horvat SA, et al. Preinjury warfarin worsens outcome in elderly patients who fall from standing. J Trauma. 2009;66(6):1518–22 discussion1523–4.CrossRefPubMed
19.
go back to reference Karni A, Holtzman R, Bass T, et al. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Am Surg. 2001;67(11):1098–100.PubMed Karni A, Holtzman R, Bass T, et al. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Am Surg. 2001;67(11):1098–100.PubMed
20.
go back to reference Franko J, Kish KJ, O'Connell BG, et al. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma. 2006;61(1):107–10.CrossRefPubMed Franko J, Kish KJ, O'Connell BG, et al. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma. 2006;61(1):107–10.CrossRefPubMed
21.
go back to reference Bonville DJ, Ata A, Jahraus CB, et al. Impact of preinjury warfarin and antiplatelet agents on outcomes of trauma patients. Surgery. 2011;150(4):861–8.CrossRefPubMed Bonville DJ, Ata A, Jahraus CB, et al. Impact of preinjury warfarin and antiplatelet agents on outcomes of trauma patients. Surgery. 2011;150(4):861–8.CrossRefPubMed
22.
go back to reference Grandhi R, Harrison G, Voronovich Z, et al. Preinjury warfarin, but not antiplatelet medications, increases mortality in elderly traumatic brain injury patients. J Trauma Acute Care Surg. 2015;78(3):614–21.CrossRefPubMed Grandhi R, Harrison G, Voronovich Z, et al. Preinjury warfarin, but not antiplatelet medications, increases mortality in elderly traumatic brain injury patients. J Trauma Acute Care Surg. 2015;78(3):614–21.CrossRefPubMed
23.
go back to reference Mina AA, Knipfer JF, Park DY, et al. Intracranial complications of preinjury anticoagulation in trauma patients with head injury. J Trauma. 2002;53(4):668–72.CrossRefPubMed Mina AA, Knipfer JF, Park DY, et al. Intracranial complications of preinjury anticoagulation in trauma patients with head injury. J Trauma. 2002;53(4):668–72.CrossRefPubMed
24.
go back to reference Inamasu J, Nakatsukasa M, Miyatake S, Hirose Y. Influence of warfarin and low-dose aspirin on the outcomes of geriatric patients with traumatic intracranial hemorrhage resulting from ground-level fall. Geriatr Gerontol Int. 2012;12(4):667–72.CrossRefPubMed Inamasu J, Nakatsukasa M, Miyatake S, Hirose Y. Influence of warfarin and low-dose aspirin on the outcomes of geriatric patients with traumatic intracranial hemorrhage resulting from ground-level fall. Geriatr Gerontol Int. 2012;12(4):667–72.CrossRefPubMed
25.
go back to reference Pieracci FM, Eachempati SR, Shou J, Hydo LJ, Barie PS. Degree of anticoagulation, but not warfarin use itself, predicts adverse outcomes after traumatic brain injury in elderly trauma patients. J Trauma. 2007;63(3):525–30.CrossRefPubMed Pieracci FM, Eachempati SR, Shou J, Hydo LJ, Barie PS. Degree of anticoagulation, but not warfarin use itself, predicts adverse outcomes after traumatic brain injury in elderly trauma patients. J Trauma. 2007;63(3):525–30.CrossRefPubMed
26.
go back to reference Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefPubMed Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefPubMed
27.
go back to reference Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124(15):2450–8.CrossRefPubMed Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124(15):2450–8.CrossRefPubMed
28.
go back to reference •• Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, et al. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604.e11 This retrospective study of 448,944 US Medicare patients between 2010 and 2015 found a reduction in the risk of thromboembolic stroke, intracranial hemorrhage, and mortality for dabigatran, rivaroxaban, and apixaban when each was compared to warfarin. Reductions in intracranial hemorrhage for NOACs compared to warfarin ranged from 35%-62% (p<0.001). The harm reductions for NOACs were greatest for dabigatran and apixaban. CrossRefPubMed •• Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, et al. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604.e11 This retrospective study of 448,944 US Medicare patients between 2010 and 2015 found a reduction in the risk of thromboembolic stroke, intracranial hemorrhage, and mortality for dabigatran, rivaroxaban, and apixaban when each was compared to warfarin. Reductions in intracranial hemorrhage for NOACs compared to warfarin ranged from 35%-62% (p<0.001). The harm reductions for NOACs were greatest for dabigatran and apixaban. CrossRefPubMed
29.
go back to reference Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thromb Haemost. 2016;115(05):975–86. Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thromb Haemost. 2016;115(05):975–86.
30.
go back to reference Kim IS, Kim HJ, Kim TH, Uhm JS, Joung B, Lee MH, et al. Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: a systematic review and meta-analysis. J Cardiol. 2018;72(2):105–12.CrossRefPubMed Kim IS, Kim HJ, Kim TH, Uhm JS, Joung B, Lee MH, et al. Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: a systematic review and meta-analysis. J Cardiol. 2018;72(2):105–12.CrossRefPubMed
31.
go back to reference Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of gastrointestinal bleeding in patients taking non–vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(11):1674–83.CrossRefPubMed Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of gastrointestinal bleeding in patients taking non–vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(11):1674–83.CrossRefPubMed
32.
go back to reference Bando S, Nishikado A, Hiura N, Ikeda S, Kakutani A, Yamamoto K, et al. Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: analysis of the Shikoku Rivaroxaban Registry Trial (SRRT). J Cardiol. 2018;71(2):197–201.CrossRefPubMed Bando S, Nishikado A, Hiura N, Ikeda S, Kakutani A, Yamamoto K, et al. Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: analysis of the Shikoku Rivaroxaban Registry Trial (SRRT). J Cardiol. 2018;71(2):197–201.CrossRefPubMed
33.
go back to reference Paciaroni M, Agnelli G, Falocci N, Tsivgoulis G, Vadikolias K, Liantinioti C, et al. Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non–vitamin-K Oral anticoagulants (RAF-NOAC s) study. J Am Heart Assoc. 2017;6(12):e007034.CrossRefPubMedPubMedCentral Paciaroni M, Agnelli G, Falocci N, Tsivgoulis G, Vadikolias K, Liantinioti C, et al. Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non–vitamin-K Oral anticoagulants (RAF-NOAC s) study. J Am Heart Assoc. 2017;6(12):e007034.CrossRefPubMedPubMedCentral
35.
go back to reference • Batey M, Hecht J, Callahan C, Wahl W. Direct oral anticoagulants do not worsen traumatic brain injury after low-level falls in the elderly. Surgery. 2018;164(4):814–9 This retrospective study of elderly trauma patients requiring neurosurgical care at 19 regional hospitals showed that patients on warfarin had more neurosurgical procedures compared to patients on a NOAC (18% vs. 2.8%, p<0.02). Warfarin users also required more red cell and plasma transfusions. However, there were no differences in mortality between patients taking warfarin or a NOAC. No neurologic outcomes were reported. CrossRefPubMed • Batey M, Hecht J, Callahan C, Wahl W. Direct oral anticoagulants do not worsen traumatic brain injury after low-level falls in the elderly. Surgery. 2018;164(4):814–9 This retrospective study of elderly trauma patients requiring neurosurgical care at 19 regional hospitals showed that patients on warfarin had more neurosurgical procedures compared to patients on a NOAC (18% vs. 2.8%, p<0.02). Warfarin users also required more red cell and plasma transfusions. However, there were no differences in mortality between patients taking warfarin or a NOAC. No neurologic outcomes were reported. CrossRefPubMed
36.
go back to reference • Zeeshan M, Jehan F, O’Keeffe T, Khan M, Hamidi M, Gries L, et al. The novel oral anticoagulants (NOACs) have worse outcomes compared with warfarin in patients with intracranial hemorrhage after TBI. J Trauma Acute Care Surg. 2018;85(5):915–20 Zeeshan et al prospectively examined 210 patients with TBI on oral anticoagulation with two groups matched based on warfarin or NOAC use. NOAC users had a higher risk of intracranial hemorrhage progression, neurosurgical intervention, and TBI-associated mortality. Specific data on the NOAC agent used was not reported. CrossRefPubMed • Zeeshan M, Jehan F, O’Keeffe T, Khan M, Hamidi M, Gries L, et al. The novel oral anticoagulants (NOACs) have worse outcomes compared with warfarin in patients with intracranial hemorrhage after TBI. J Trauma Acute Care Surg. 2018;85(5):915–20 Zeeshan et al prospectively examined 210 patients with TBI on oral anticoagulation with two groups matched based on warfarin or NOAC use. NOAC users had a higher risk of intracranial hemorrhage progression, neurosurgical intervention, and TBI-associated mortality. Specific data on the NOAC agent used was not reported. CrossRefPubMed
37.
go back to reference Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e152S–84S.CrossRefPubMedPubMedCentral Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e152S–84S.CrossRefPubMedPubMedCentral
38.
go back to reference Frontera JA, Lewin JJ III, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage. Neurocrit Care. 2016;24(1):6–46.CrossRefPubMed Frontera JA, Lewin JJ III, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage. Neurocrit Care. 2016;24(1):6–46.CrossRefPubMed
39.
go back to reference Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–43.CrossRefPubMedPubMedCentral Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–43.CrossRefPubMedPubMedCentral
40.
go back to reference Steiner T, Poli S, Griebe M, Husing J, Hajda J, Freiberger A, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15:566–73.CrossRefPubMed Steiner T, Poli S, Griebe M, Husing J, Hajda J, Freiberger A, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15:566–73.CrossRefPubMed
41.
go back to reference Johansen M, Wikkelso A, Lunde J, Wetterslev J, Afshari A. Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. Cochrane Database Syst Rev. 2015;7:CD010555. Johansen M, Wikkelso A, Lunde J, Wetterslev J, Afshari A. Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. Cochrane Database Syst Rev. 2015;7:CD010555.
42.
go back to reference Ko D, Razouki Z, Otis J, Marulanda-Londoño E, Hylek EM. Anticoagulation reversal in vitamin K antagonist–associated intracerebral hemorrhage: a systematic review. J Thromb Thrombolysis. 2018;23:1–1. Ko D, Razouki Z, Otis J, Marulanda-Londoño E, Hylek EM. Anticoagulation reversal in vitamin K antagonist–associated intracerebral hemorrhage: a systematic review. J Thromb Thrombolysis. 2018;23:1–1.
44.
go back to reference Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386(9994):680–90.CrossRefPubMed Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386(9994):680–90.CrossRefPubMed
45.
go back to reference Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–20.CrossRefPubMed Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–20.CrossRefPubMed
46.
go back to reference Heo YA. Andexanet alfa: first global approval. Drugs. 2018;20:1–7. Heo YA. Andexanet alfa: first global approval. Drugs. 2018;20:1–7.
47.
go back to reference Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–24.CrossRefPubMed Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–24.CrossRefPubMed
48.
go back to reference • Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–41 This is a prospective, multi-center, open-label study of the safety and efficacy of andexanet alfa as a reversal agent of a Xa inhibitor in the setting of acute major bleeding. At 12 hours post-infusion, 79% (95% CI: 64%–89%) had good or excellent clinical hemostasis but longer interval outcomes are not reported for hemostasis. Eighteen percent of patients had a thrombotic event within thirty days. CrossRefPubMedPubMedCentral • Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–41 This is a prospective, multi-center, open-label study of the safety and efficacy of andexanet alfa as a reversal agent of a Xa inhibitor in the setting of acute major bleeding. At 12 hours post-infusion, 79% (95% CI: 64%–89%) had good or excellent clinical hemostasis but longer interval outcomes are not reported for hemostasis. Eighteen percent of patients had a thrombotic event within thirty days. CrossRefPubMedPubMedCentral
49.
go back to reference Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost. 2017;117(02):238–45.CrossRefPubMedPubMedCentral Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost. 2017;117(02):238–45.CrossRefPubMedPubMedCentral
50.
go back to reference Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016;12:35–44.PubMedPubMedCentral Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016;12:35–44.PubMedPubMedCentral
51.
go back to reference Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother. 2009;7(3):159–66.CrossRefPubMed Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother. 2009;7(3):159–66.CrossRefPubMed
52.
go back to reference Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.CrossRefPubMed Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.CrossRefPubMed
53.
go back to reference Granziera S, Cohen AT, Nante G, Manzato E, Sergi G. Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm. Am Med Dir Assoc. 2015;16(5):358–64.CrossRef Granziera S, Cohen AT, Nante G, Manzato E, Sergi G. Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm. Am Med Dir Assoc. 2015;16(5):358–64.CrossRef
54.
go back to reference Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MA. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118(6):612–7.CrossRefPubMed Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MA. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118(6):612–7.CrossRefPubMed
55.
go back to reference Monette J, Gurwitz JH, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc. 1997;45:1060–5.CrossRefPubMed Monette J, Gurwitz JH, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc. 1997;45:1060–5.CrossRefPubMed
56.
go back to reference Ogilvie IM, Newton N, Weiner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–45.CrossRefPubMed Ogilvie IM, Newton N, Weiner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–45.CrossRefPubMed
57.
go back to reference Zhu WG, Xiong QM, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Tex Heart Inst J. 2015;42(1):6–15.CrossRefPubMedPubMedCentral Zhu WG, Xiong QM, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Tex Heart Inst J. 2015;42(1):6–15.CrossRefPubMedPubMedCentral
58.
go back to reference Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA Study. J Am Col Cardiol. 2011;58(4):395–401.CrossRef Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA Study. J Am Col Cardiol. 2011;58(4):395–401.CrossRef
59.
go back to reference Palareti G, Cosmi B. Bleeding with anticoagulation therapy—who is at risk, and how best to identify such patients. Thromb Haemost. 2009;102:268–78.CrossRefPubMed Palareti G, Cosmi B. Bleeding with anticoagulation therapy—who is at risk, and how best to identify such patients. Thromb Haemost. 2009;102:268–78.CrossRefPubMed
60.
go back to reference Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;1513:713–9.CrossRef Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;1513:713–9.CrossRef
61.
go back to reference January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Conti JB, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76 Gall.CrossRefPubMed January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Conti JB, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76 Gall.CrossRefPubMed
62.
go back to reference Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Vlades M, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013;142:179–84.CrossRef Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Vlades M, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013;142:179–84.CrossRef
63.
go back to reference Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes M, et al. The HAS-BLED score has better prediction accuracy for major bleed than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62(23):2199–204.CrossRefPubMed Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes M, et al. The HAS-BLED score has better prediction accuracy for major bleed than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62(23):2199–204.CrossRefPubMed
64.
go back to reference Harvey NC, Johansson H, Odén A, Karlsson MK, Rosengren BE, Ljunggren Ö, et al. FRAX predicts incident falls in elderly men: findings from MrOs Sweden. Osteoporos Int. 2016;27(1):267–74.CrossRefPubMed Harvey NC, Johansson H, Odén A, Karlsson MK, Rosengren BE, Ljunggren Ö, et al. FRAX predicts incident falls in elderly men: findings from MrOs Sweden. Osteoporos Int. 2016;27(1):267–74.CrossRefPubMed
65.
go back to reference Holloway KL, Kotowicz MA, Lane SE, Brennan SL, Pasco JA. FRAX (Aus) and falls risk: association in men and women. Bone. 2015;76:1–4.CrossRefPubMed Holloway KL, Kotowicz MA, Lane SE, Brennan SL, Pasco JA. FRAX (Aus) and falls risk: association in men and women. Bone. 2015;76:1–4.CrossRefPubMed
66.
go back to reference Gleize F, Zmudka J, Lefresne Y, Serot JM, Berteaux B, Jouanny P. Fragility assessment in primary care: which tools for predicting what? Geriatr Psychol Nuropsychiatr Viell. 2015;13(3):289–97. Gleize F, Zmudka J, Lefresne Y, Serot JM, Berteaux B, Jouanny P. Fragility assessment in primary care: which tools for predicting what? Geriatr Psychol Nuropsychiatr Viell. 2015;13(3):289–97.
67.
go back to reference Sharifi F, Fakhrzadeh H, Memari A, Najafi B, Nazari N, Khoee MA, et al. Predicting risk of the fall among aged adult residents of a nursing home. Arch Gerontol Geriatr. 2015;61(2):124–30.CrossRefPubMed Sharifi F, Fakhrzadeh H, Memari A, Najafi B, Nazari N, Khoee MA, et al. Predicting risk of the fall among aged adult residents of a nursing home. Arch Gerontol Geriatr. 2015;61(2):124–30.CrossRefPubMed
68.
go back to reference Lee J, Geller AI, Strasser DC. Analytical review: focus on fall screening assessments. PMR. 2013;5:609–21.CrossRef Lee J, Geller AI, Strasser DC. Analytical review: focus on fall screening assessments. PMR. 2013;5:609–21.CrossRef
Metadata
Title
Consideration of Anticoagulation: Surgical Care for the Elderly in Current Geriatrics Reports
Authors
Jared R. Gallaher
Joanna Grudziak
Martin A. Schreiber
Publication date
01-09-2019
Publisher
Springer US
Published in
Current Geriatrics Reports / Issue 3/2019
Electronic ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-019-00290-w

Other articles of this Issue 3/2019

Current Geriatrics Reports 3/2019 Go to the issue

Physical Therapy and Rehabilitation (O Addison, Section Editor)

Review of Forward-Head Posture and Vestibular Deficits in Older Adults

Underserved Populations (H Fernandez, Section Editor)

Aging Patients in Correctional Settings

Physical Therapy and Rehabilitation (O Addison, Section Editor)

Body Composition and Falls Risk in Older Adults

Physical Therapy and Rehabilitation (O Addison, Section Editor)

In-Home Video Telehealth for Dementia Management: Implications for Rehabilitation

Physical Therapy and Rehabilitation (O Addison, Section Editor)

Mobility Challenges Among Older Adult Mobility Device Users

Physical Therapy and Rehabilitation (O Addison, Section Editor)

Living In Place: the Impact of Smart Technology